Brian Gastman

8.0k total citations
175 papers, 4.5k citations indexed

About

Brian Gastman is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Brian Gastman has authored 175 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 48 papers in Molecular Biology and 41 papers in Immunology. Recurrent topics in Brian Gastman's work include CAR-T cell therapy research (42 papers), Cutaneous Melanoma Detection and Management (38 papers) and Cancer Immunotherapy and Biomarkers (35 papers). Brian Gastman is often cited by papers focused on CAR-T cell therapy research (42 papers), Cutaneous Melanoma Detection and Management (38 papers) and Cancer Immunotherapy and Biomarkers (35 papers). Brian Gastman collaborates with scholars based in United States, United Kingdom and Germany. Brian Gastman's co-authors include Hannah Rabinowich, Leslie A. Goldstein, Theresa L. Whiteside, Jie Han, Lukas W. Pfannenstiel, Scott E. Strome, Torsten E. Reichert, Andrei I. Chapoval, Daniel E. Johnson and Jennifer S. Ko and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Brian Gastman

168 papers receiving 4.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Gastman United States	37	2.0k	1.7k	1.7k	768	495	175	4.5k
Stefan Nierkens Netherlands	44	1.9k 1.0×	2.8k 1.6×	1.1k 0.6×	489 0.6×	279 0.6×	197	5.7k
Walter C. Darbonne United States	26	1.9k 0.9×	1.5k 0.9×	2.7k 1.6×	622 0.8×	272 0.5×	46	6.1k
Noelyn M. Kljavin United States	24	1.3k 0.7×	1.8k 1.0×	1.5k 0.9×	333 0.4×	358 0.7×	29	4.1k
Camilla Jandus Switzerland	34	1.4k 0.7×	3.3k 1.9×	1.6k 0.9×	232 0.3×	415 0.8×	82	4.7k
Michael D. Rosenblum United States	36	2.2k 1.1×	4.0k 2.3×	1.4k 0.8×	377 0.5×	264 0.5×	74	6.5k
Claudia Wickenhauser Germany	37	1.1k 0.6×	1.1k 0.6×	1.4k 0.8×	433 0.6×	324 0.7×	199	4.3k
Michael V. Volin United States	39	1.4k 0.7×	1.6k 0.9×	1.7k 1.0×	271 0.4×	333 0.7×	69	4.9k
Günther F.L. Hofbauer Switzerland	36	1.7k 0.9×	1.1k 0.6×	1.3k 0.7×	1.4k 1.8×	351 0.7×	161	4.8k
Scott W. Binder United States	30	1.2k 0.6×	1.0k 0.6×	888 0.5×	781 1.0×	386 0.8×	89	3.8k
Norio Komatsu Japan	44	1.2k 0.6×	1.4k 0.8×	2.6k 1.5×	267 0.3×	443 0.9×	384	6.7k

Countries citing papers authored by Brian Gastman

Since Specialization

Citations

This map shows the geographic impact of Brian Gastman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Gastman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Gastman more than expected).

Fields of papers citing papers by Brian Gastman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Gastman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Gastman. The network helps show where Brian Gastman may publish in the future.

Co-authorship network of co-authors of Brian Gastman

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Gastman. A scholar is included among the top collaborators of Brian Gastman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Gastman. Brian Gastman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kluger, Harriet M., Götz Ulrich Grigoleit, Sajeve Thomas, et al.. (2025). Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Communications. 45(10). 1229–1234. 3 indexed citations

Coukos, George, Marco Donia, Brian Gastman, et al.. (2025). The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee. Journal for ImmunoTherapy of Cancer. 13(11). e013420–e013420.

Ferris, Robert L., Rom S. Leidner, Christine H. Chung, et al.. (2025). Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 13(8). e011633–e011633. 1 indexed citations

Phoon, Yee Peng, Jared E. Lopes, Lukas W. Pfannenstiel, et al.. (2024). Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics. Journal for ImmunoTherapy of Cancer. 12(4). e008066–e008066. 2 indexed citations

Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immuno-Oncology Technology. 20. 100591–100591. 7 indexed citations

Long, Georgina V., John M. Kirkwood, Christoph Höeller, et al.. (2023). Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).. Journal of Clinical Oncology. 41(16_suppl). 9504–9504. 8 indexed citations

Shen, Alan, Patricia Rayman, Ying Ni, et al.. (2023). Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma. Clinical Cancer Research. 30(3). 564–574. 1 indexed citations

Biswas, Sudipta, Kai Kang, Kwok Peng Ng, et al.. (2023). Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy. Cell Reports. 42(8). 113016–113016. 2 indexed citations

Olson, Daniel J., Brian Gastman, Madan Jagasia, et al.. (2023). HSR23-110: Immune Checkpoint Inhibitor (ICI) Treatment After Progression on Anti–PD-1 Therapy in Advanced Melanoma: A Systematic Review of the Literature. Journal of the National Comprehensive Cancer Network. 21(3.5). HSR23–110.

10.

Chen, Xing, Junjie Zhao, Tomasz Herjan, et al.. (2022). IL-17–induced HIF1α drives resistance to anti–PD-L1 via fibroblast-mediated immune exclusion. The Journal of Experimental Medicine. 219(6). 31 indexed citations

11.

Fu, Dechen, Yee Peng Phoon, Claudia Cabrera, et al.. (2022). MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma. Cell Death and Disease. 13(1). 63–63. 15 indexed citations

12.

Jarell, Abel, Brian Gastman, Eddy C. Hsueh, et al.. (2022). Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. Journal of the American Academy of Dermatology. 87(6). 1312–1320. 23 indexed citations

13.

Azzato, Elizabeth M., Zheng Jin Tu, Ying Ni, et al.. (2020). Targeted next generation sequencing (NGS) to classify melanocytic neoplasms. Journal of Cutaneous Pathology. 47(8). 691–704. 18 indexed citations

14.

Pfannenstiel, Lukas W., et al.. (2019). Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer. Cancer Immunology Research. 7(3). 510–525. 38 indexed citations

15.

Chen, Xing, Gang Cai, Caini Liu, et al.. (2018). IL-17R–EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells. The Journal of Experimental Medicine. 216(1). 195–214. 88 indexed citations

16.

Sun, Lillian, Pauline Funchain, Jung Min Song, et al.. (2018). Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. Journal for ImmunoTherapy of Cancer. 6(1). 36–36. 74 indexed citations

17.

Ascha, Mona, Mustafa Ascha, & Brian Gastman. (2017). Identification of Risk Factors in Lymphatic Surgeries for Melanoma. Annals of Plastic Surgery. 79(5). 509–515. 12 indexed citations

18.

Manyam, Bindu V., Adam Garsa, R Chin, et al.. (2016). A Multi-institutional Comparison of Outcomes of Immunocompromised and Immunocompetent Patients Treated With Surgery and Radiation Therapy for Cutaneous Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 94(4). 948–948. 1 indexed citations

19.

Zhang, Yue, Lukas W. Pfannenstiel, Carolina L. Montes, et al.. (2011). Interleukin-7 Inhibits Tumor-Induced CD27−CD28− Suppressor T Cells: Implications for Cancer Immunotherapy. Clinical Cancer Research. 17(15). 4975–4986. 28 indexed citations

20.

Zhang, Xiaoyu, Caroline Voskens, Michelle A. Sallin, et al.. (2009). CD137 Promotes Proliferation and Survival of Human B Cells. The Journal of Immunology. 184(2). 787–795. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact